Your browser doesn't support javascript.
loading
Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
Knittel, Delphine; Gadzinski, Adeline; Hua, Stéphane; Denizeau, Jordan; Savatier, Alexandra; de la Rochère, Philippe; Boulain, Jean-Claude; Amigorena, Sebastian; Piaggio, Eliane; Sedlik, Christine; Léonetti, Michel.
Afiliação
  • Knittel D; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
  • Gadzinski A; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
  • Hua S; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
  • Denizeau J; Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France.
  • Savatier A; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
  • de la Rochère P; Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France.
  • Boulain JC; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France.
  • Amigorena S; Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France.
  • Piaggio E; Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France.
  • Sedlik C; Institut Curie, Centre de Recherche, Paris 75005, France; INSERM, U932, Paris F-75005, France; Centre d'Investigation Clinique Biothérapie CICBT 507, Institut Curie, Paris F-75005, France.
  • Léonetti M; Commissariat à l'Energie Atomique et aux Energies Alternatives, Institut de Biologie et Technologies de Saclay, Service de Pharmacologie et d'Immunoanalyse, Laboratoire d'Etudes et de Recherches en Immunoanalyse, Gif-Sur-Yvette F-91191, France. Electronic address: michel.leonetti@cea.fr.
Vaccine ; 34(27): 3093-3101, 2016 06 08.
Article em En | MEDLINE | ID: mdl-27154391
ABSTRACT
Heparan sulfates (HS) are carbohydrate moieties of HS proteoglycans (HSPGs). They often represent alternative attachment points for proteins or microorganisms targeting receptors. HSPGs, which are ubiquitously expressed, thereby participate in numerous biological processes. We previously showed that MHC class II-restricted antigen presentation is increased when antigens are coupled to HS ligands, suggesting that HSPGs might contribute to adaptive immune responses. Here, we examined if HSPG targeting influences other aspects of immune responses. We found that coupling of an HS ligand to the antigen increases antigen presentation to CD4(+) and CD8(+) T-cells after antigen targeting to membrane immunoglobulins or to MHC-II molecules. Moreover, this increased stimulating capacity correlates with an enhanced CD8(+) immune response in mice. Last, animals control more effectively the growth of Ova-expressing tumour cells when they are immunized with an Ova construct targeting HSPGs and MHC-II molecules. Our results indicate that ubiquitous molecules can influence both MHC class I- and MHC class II-restricted antigen presentation and behave as co-receptors during T-cell stimulation. Moreover, they suggest that tumour-antigens endowed with the ability to target both HSPGs and MHC-II molecules could be of value to increase CD8(+) immune response and control tumour-growth, opening new perspectives for the design of highly immunogenic protein-based vaccines.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apresentação de Antígeno / Linfócitos T CD8-Positivos / Proteoglicanas de Heparan Sulfato Limite: Animals Idioma: En Revista: Vaccine Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Apresentação de Antígeno / Linfócitos T CD8-Positivos / Proteoglicanas de Heparan Sulfato Limite: Animals Idioma: En Revista: Vaccine Ano de publicação: 2016 Tipo de documento: Article País de afiliação: França